A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials for the ...

Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis (RMS) trials, revealing that deaths from ...

Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...

A pair of Sage Therapeutics veterans has launched a neurology-focused startup armed with $106 million and a clinical-stage ...

Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s ...

Pulnovo Medical, a Chinese medtech focused on therapies that target pulmonary hypertension and heart failure, hauled in ...

Roche’s Foundation Medicine is deepening its longstanding ties with Bristol Myers Squibb as the companies team up on a new ...

With a few chemical tweaks and some dutiful protein partners, a new biotech from Flagship Pioneering thinks it has cracked ...

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another trial—leading Gilead to pull further away from their once wide-ranging | ...

Replimune is saying goodbye to a further 161 employees across two Massachusetts sites as the company continues to reel from ...

But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational ...